Literature DB >> 374611

Flow cytometric analysis of adriamycin-perturbed mouse mammary tumors.

L A Dethlefsen, R M Riley, J L Roti Roti.   

Abstract

The effects of a single intraperitoneal injection of adriamycin (10 mg/kg) on a fast-growing C3H mouse mammary tumor (S102F) have been analyzed volumetrically, biochemically, autoradiographically and flow cytometrically. Mathematical simulation of the data was also used to aid in the interpretation of the recovery kinetics. This dose of adriamycin did not induce regression in tumor volume but did inhibit the growth rate for 4-5 days. 3H-TdR incorporation was gradually inhibited to reach a low of 20% of control at 24 and 36 hr and then recovered back to control by 96 hr after adriamycin treatment. The flow cytometric analysis also showed a marked reduction in the relative fraction of cells in the S-phase with a minimum of 23% of control at 72 hr; however, in contrast to the 3H-TdR incorporation data, the fraction of cells in the S-phase was only at 39% of control at 96 hr after the adriamycin injection. Since the 3H-TdR incorporation data disagreed with the flow cytometry data, autoradiographic analysis was also done at selected times after the adriamycin injections, and qualitatively, this analysis confirms the flow cytometry data in that the labeling index was 29% of control at 96 hr after adriamycin. The mitotic index also dropped from 8 to 1%, respectively, for controls and at 96 hr posttreatment. The degenerate index was about 1% in control tumors and no increase was observed in treated tumors. Adriamycin-induced cell-cycle delay occurs predominately in G1 and G2 but there is also an apparent minor delay in the transit across the S-phase and some apparent cytotoxicity in G2 and/or M. The long delay in volumetric growth appears to be due to the extended cell-cycle delay rather than extensive cell killing.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 374611     DOI: 10.1177/27.1.374611

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  5 in total

1.  Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Ramos; D Donato
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.

Authors:  Alberta Bergamo; Tina Riedel; Paul J Dyson; Gianni Sava
Journal:  Invest New Drugs       Date:  2014-10-23       Impact factor: 3.850

Review 3.  Experimental chemotherapy studies: intercomparison of assays.

Authors:  P R Twentyman
Journal:  Br J Cancer Suppl       Date:  1980-04

4.  Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

5.  In vivo tumour-cell proliferation after adriamycin treatment.

Authors:  R Rowley; H A Hopkins; W B Looney
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.